Fig. 2.

Patients enrolled in the Measure Up 1 and Measure Up 2 studies who achieved a ADerm-SS Skin Pain Improvement ≥ 4,^a b ADerm-SS Skin Pain 0/1,^b c ADerm-SS TSS-7 Improvement ≥ 28,^c d ADerm-SS TSS-7 0–11,^d e POEM Improvement ≥ 4,^e and f POEM 0–2^f during the double-blind period (NRI-C). Comparisons at time points in shaded boxes were multiplicity controlled. *Nominal P < 0.001 versus placebo for all time points. **Multiplicity adjusted P < 0.001 versus placebo. ^aAssessed in patients with ADerm-SS Skin Pain ≥ 4 at baseline. ^bAssessed in patients with ADerm-SS Skin Pain ≥ 2 at baseline. ^cAssessed in patients with ADerm-SS TSS-7 ≥ 28 at baseline. ^dAssessed in patients with ADerm-SS TSS-7 ≥ 12 at baseline. ^eAssessed in patients with POEM ≥ 4 at baseline. ^fAssessed in patients with POEM scores ≥ 3 at baseline. ADerm-SS Atopic Dermatitis Symptom Scale, CI confidence interval, NRI-C non-responder imputation incorporating multiple imputation for missing data due to COVID-19, PBO placebo, POEM Patient-Oriented Eczema Measure, TSS-7 7-item Total Symptom Score, UPA upadacitinib